Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Q3 2020 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Oct 29, 2020 / 12:00PM GMT
Release Date Price: €0.9788 (-11.14%)
Operator

Good morning, my name is Julianne, and I will be your conference operator today. At this time, I would like to welcome everyone to the Lexicon Pharmaceuticals' Third Quarter 2020 Financial Results Call. (Operator Instructions)

I would now like to hand the conference over to your first speaker today, Chas Schultz. You may begin.

Chas Schultz
Lexicon Pharmaceuticals, Inc. - Executive Director of Corporate Communications & Patient Advocacy

Thank you, Julianne. Good morning, and welcome to the Lexicon Pharmaceuticals Third Quarter 2020 Financial Results and Clinical Update Conference Call. Joining me today are Lonnel Coats, Lexicon's President and Chief Executive Officer; Dr. Praveen Tyle, Lexicon's Executive Vice President of Research and Development; and Jeff Wade, Lexicon's Executive Vice President of Corporate and Administrative Affairs and Chief Financial Officer.

Earlier today, Lexicon issued a press release announcing our financial results for the third quarter of 2020, which is available on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot